AstraZeneca Near Decision on Suicide-Linked Drug, CEO Says
This article is for subscribers only.
AstraZeneca Plc will decide in a “few weeks” whether to pursue independently a drug for psoriasis after its partner dropped out of the project, said Pascal Soriot, chief executive officer of the U.K. drug company.
Amgen Inc. terminated the development deal on May 22 after patients showed signs of considering suicide, which could lead to regulators requiring a warning on the drug’s label.